Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

Albireo Pharma stock price, quote, forecast and news

ALBO
US01345P1066
A2DF99

Price

44.15
Today +/-
+0
Today %
+0 %
P

Albireo Pharma stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Albireo Pharma stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Albireo Pharma stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Albireo Pharma stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Albireo Pharma's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Albireo Pharma Stock Price History

DateAlbireo Pharma Price
3/2/202344.15 undefined
3/1/202344.25 undefined

Albireo Pharma Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Albireo Pharma, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Albireo Pharma from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Albireo Pharma’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Albireo Pharma. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Albireo Pharma’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Albireo Pharma’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Albireo Pharma’s growth potential.

Albireo Pharma Revenue, EBIT and net profit per share

DateAlbireo Pharma RevenueAlbireo Pharma EBITAlbireo Pharma Net Income
2028e747.61 M undefined0 undefined228.95 M undefined
2027e636.96 M undefined327.31 M undefined267.78 M undefined
2026e437.82 M undefined167.17 M undefined133.8 M undefined
2025e247.64 M undefined5.59 M undefined12.55 M undefined
2024e148.29 M undefined-65.99 M undefined-78.08 M undefined
2023e61.91 M undefined-136.58 M undefined-139.3 M undefined
2022e35.07 M undefined-154.13 M undefined-170.05 M undefined
202140.58 M undefined-123.49 M undefined-34.03 M undefined
20208.31 M undefined-96.27 M undefined-107.63 M undefined
20199.64 M undefined-61.11 M undefined-62.72 M undefined
201812.74 M undefined-37.89 M undefined-46.11 M undefined
20170 undefined-24.58 M undefined-24.41 M undefined
201611.36 M undefined-12.29 M undefined-16.35 M undefined
20150 undefined-13.97 M undefined-13.76 M undefined
20140 undefined-19.77 M undefined-18.74 M undefined
20130 undefined-19.26 M undefined-14.13 M undefined
20120 undefined-20.59 M undefined-19.34 M undefined
20110 undefined-19.3 M undefined-20.75 M undefined
20100 undefined-23.22 M undefined-10.59 M undefined
20090 undefined-37.16 M undefined-38.29 M undefined
20080 undefined-43.32 M undefined-43.27 M undefined
20070 undefined-47.35 M undefined-43.36 M undefined
20060 undefined-24.33 M undefined-27.01 M undefined
20050 undefined-7.53 M undefined-8.67 M undefined
20040 undefined-3.39 M undefined-3.38 M undefined
20030 undefined-770,000 undefined-770,000 undefined

Albireo Pharma Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)EBIT (M)EBIT MARGIN (%)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
20032004200520062007200820092010201120122013201420152016201720182019202020212022e2023e2024e2025e2026e2027e2028e
00000000000001101298403561148247437636747
-----------------25.00-11.11400.00-12.5074.29142.6266.8976.9245.5417.45
------------------97.50-------
000000000000000000390000000
0-3-7-24-47-43-37-23-19-20-19-19-13-12-24-37-61-96-123-154-136-6551673270
--------------109.09--308.33-677.78-1,200.00-307.50-440.00-222.95-43.922.0238.2251.42-
0-3-8-27-43-43-38-10-20-19-14-18-13-16-24-46-62-107-34-170-139-7812133267228
--166.67237.5059.26--11.63-73.68100.00-5.00-26.3228.57-27.7823.0850.0091.6734.7872.58-68.22400.00-18.24-43.88-115.381,008.33100.75-14.61
0.280.280.280.510.750.790.21.040.360.520.711.372.131.247.8211.712.4415.9819.220000000
--------------------------
Details

Keystats

ⓘ

Revenue and Growth

The Albireo Pharma Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Albireo Pharma is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (k)INVENTORIES (k)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (k)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (k)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
200420052006200720082009201020112012201320142015201620172018201920202021
0.417.58090.354.628.938.739.139.824.640.828.729.953.2163.9131.8251.3248.11
000000000000000003.27
00000000000040000000
00000000000000000194
0.10.10.51.10.50.60.50.40.30.30.30.10.61.10.91010.617.36
0.517.680.591.455.129.539.239.540.124.941.128.830.954.3164.8141.8261.9268.93
0.70.61.73.93.732.31.610.50.3000.20.25.34.612.67
000000000000000000
000000000000000000
10020030010010010000000020000000
00000000000018.117.317.317.317.317.26
00.200.1000000000.50.80.40.71.93.19
0.8124.13.83.12.31.610.50.3018.818.317.923.323.833.12
1.318.682.595.558.932.641.541.141.125.441.428.849.772.6182.7165.1285.7302.05
1002002002002003001002002002006000100100100100200193
4.829.1116.9171.5176.8188.5212.3226.9247.8252.1287.2288.561.3114.5214.7245.8456.5475.39
-4.2-12.8-39.8-83.2-126.5-164.8-175.3-196.1-215.4-229.6-248.3-262.1-25.9-50.4-96.5-159.2-266.8-300.85
000-0.1000000001.514.36.5-8.61.11
000000000000000000
0.716.577.388.450.52437.13132.622.739.526.43765.2122.693.2181.3175.84
0.21.62.20.8120.20.30.20.20.40.211.44.44.85.36.52
0.10.42.76.77.62.432.42.11.41.41.97.56.18.21419.737.35
0.20.30.41.50.500.10.10.10001.10.50.30.10.31.48
000000000000000000
0000000000003.100000
0.52.35.399.14.43.32.82.41.61.82.112.7812.918.925.345.35
00000000000000009.610
000000000000000000
000004.21.17.36.110.10.400505369.571.09
000004.21.17.36.110.10.400505379.181.1
0.52.35.399.18.64.410.18.52.61.92.512.7862.971.9104.4126.44
1.218.882.697.459.632.641.541.141.125.341.428.949.773.2185.5165.1285.7302.28
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Albireo Pharma provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Albireo Pharma's financial health and stability.

Assets

Albireo Pharma's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Albireo Pharma must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Albireo Pharma after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Albireo Pharma's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES (M)TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
2003200420052006200720082009201020112012201320142015null201620172018201920202021
0-3-8-22-43-43-38-10-20-19-14-18-13-13-16-24-46-62-107-34
00000000000000000000
00000000000000000000
002312-2-131-1-50003-22-10-4-9
001365541100004-1171911-64
00000000000000000000
00000000000000000000
0-2-3-15-34-35-34-18-16-18-18-18-12-12-8-27-26-52-101-107
000-1-2000000000000000
000-1-2824-65000000254000102
0000-2525-66000000254000103
00000000000000000000
00000000000000-2-30090
02198047082817190320094894231962
132179480828171933400745139232202
102-1000000320000440140
00000000000000000000
001762-15-10-311500-1516-12-122423110-32119-3
-0.89-2.99-4.26-16.89-37.69-35.9-34.67-18.44-16.76-18.68-18.77-18.2-12.540-8.78-27.76-26.86-53.46-101.11-108.02
00000000000000000000

Albireo Pharma stock margins

The Albireo Pharma margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Albireo Pharma. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Albireo Pharma.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Albireo Pharma's sales revenue. A higher gross margin percentage indicates that the Albireo Pharma retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Albireo Pharma's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Albireo Pharma's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Albireo Pharma's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Albireo Pharma. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Albireo Pharma's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Albireo Pharma Margin History

Albireo Pharma Gross marginAlbireo Pharma Profit marginAlbireo Pharma EBIT marginAlbireo Pharma Profit margin
2028e96.66 %0 %30.62 %
2027e96.66 %51.39 %42.04 %
2026e96.66 %38.18 %30.56 %
2025e96.66 %2.26 %5.07 %
2024e96.66 %-44.5 %-52.65 %
2023e96.66 %-220.6 %-225 %
2022e96.66 %-439.46 %-484.87 %
202196.66 %-304.31 %-83.86 %
202096.66 %-1,158.48 %-1,295.19 %
201996.66 %-633.92 %-650.62 %
201896.66 %-297.41 %-361.93 %
201796.66 %0 %0 %
201696.66 %-108.19 %-143.93 %
201596.66 %0 %0 %
201496.66 %0 %0 %
201396.66 %0 %0 %
201296.66 %0 %0 %
201196.66 %0 %0 %
201096.66 %0 %0 %
200996.66 %0 %0 %
200896.66 %0 %0 %
200796.66 %0 %0 %
200696.66 %0 %0 %
200596.66 %0 %0 %
200496.66 %0 %0 %
200396.66 %0 %0 %

Albireo Pharma Stock Sales Revenue, EBIT, Earnings per Share

The Albireo Pharma earnings per share therefore indicates how much revenue Albireo Pharma has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Albireo Pharma earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Albireo Pharma's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Albireo Pharma’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Albireo Pharma's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Albireo Pharma Revenue, EBIT and net profit per share

DateAlbireo Pharma Sales per ShareAlbireo Pharma EBIT per shareAlbireo Pharma Earnings per Share
2028e36.04 undefined0 undefined11.04 undefined
2027e30.7 undefined0 undefined12.91 undefined
2026e21.1 undefined0 undefined6.45 undefined
2025e11.94 undefined0 undefined0.61 undefined
2024e7.15 undefined0 undefined-3.76 undefined
2023e2.98 undefined0 undefined-6.71 undefined
2022e1.69 undefined0 undefined-8.2 undefined
20212.11 undefined-6.42 undefined-1.77 undefined
20200.52 undefined-6.02 undefined-6.74 undefined
20190.77 undefined-4.91 undefined-5.04 undefined
20181.09 undefined-3.24 undefined-3.94 undefined
20170 undefined-3.14 undefined-3.12 undefined
20169.16 undefined-9.91 undefined-13.19 undefined
20150 undefined-6.56 undefined-6.46 undefined
20140 undefined-14.43 undefined-13.68 undefined
20130 undefined-27.13 undefined-19.9 undefined
20120 undefined-39.6 undefined-37.19 undefined
20110 undefined-53.61 undefined-57.64 undefined
20100 undefined-22.33 undefined-10.18 undefined
20090 undefined-185.8 undefined-191.45 undefined
20080 undefined-54.84 undefined-54.77 undefined
20070 undefined-63.13 undefined-57.81 undefined
20060 undefined-47.71 undefined-52.96 undefined
20050 undefined-26.89 undefined-30.96 undefined
20040 undefined-12.11 undefined-12.07 undefined
20030 undefined-2.75 undefined-2.75 undefined

Albireo Pharma business model

Albireo Pharma Inc. is an American biopharmaceutical company specializing in the development and commercialization of innovative therapeutics for rare gastrointestinal and liver diseases. The company was founded in 2008 and is headquartered in Boston, Massachusetts. Albireo Pharma is one of the most popular companies on Eulerpool.com.

Albireo Pharma SWOT Analysis

Strengths

1. Strong product portfolio: Albireo Pharma Inc has a diverse range of innovative pharmaceutical products, allowing the company to tap into multiple markets and generate revenue from various sources.

2. Well-established brand reputation: The company has built a positive brand image over the years, known for its high-quality and effective medications.

3. Strong financial position: Albireo Pharma Inc possesses a solid financial foundation, which provides stability and resources for research and development, expansion, and other strategic initiatives.

Weaknesses

1. Dependence on key products: The company relies heavily on a few key products for a significant portion of its revenue. Any setbacks or challenges faced by these products could have a significant impact on Albireo Pharma Inc's overall performance.

2. Limited market presence: In comparison to some of its competitors, Albireo Pharma Inc has a relatively smaller market share and a more limited international presence, which limits its growth potential.

Opportunities

1. Increasing demand for innovative pharmaceuticals: The healthcare industry is witnessing a growing demand for advanced and novel therapies. Albireo Pharma Inc can seize this opportunity by introducing new and groundbreaking products that cater to unmet medical needs.

2. Expansion into new markets: The company can explore untapped markets or expand its presence in existing markets to increase its customer base and revenue streams.

3. Strategic partnerships and collaborations: Forming strategic alliances with other pharmaceutical companies or research institutions can provide access to new technologies, resources, and expertise, fueling Albireo Pharma Inc's growth.

Threats

1. Intense competition: The pharmaceutical industry is highly competitive, with numerous companies vying for market share. Albireo Pharma Inc faces challenges from both established players and new entrants, which may affect its market positioning and profitability.

2. Stringent regulations: Strict regulatory requirements and compliance standards in the pharmaceutical sector can pose hurdles for product development, testing, and marketing, potentially leading to delays or increased costs.

3. Intellectual property challenges: The company's success relies on protecting its intellectual property rights. Any infringement or legal disputes can impact Albireo Pharma Inc's ability to maintain exclusivity and suppress competition.

Albireo Pharma Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Albireo Pharma historical P/E ratio, EBIT, and P/S ratio.

Albireo Pharma shares outstanding

The number of shares was Albireo Pharma in 2023 — This indicates how many shares 19.221 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Albireo Pharma earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Albireo Pharma's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Albireo Pharma’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Albireo Pharma's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Albireo Pharma Stock splits

In Albireo Pharma's history, there have been no stock splits.
Unfortunately, there are currently no price targets and forecasts available for Albireo Pharma.

Albireo Pharma latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
9/30/2022-1.08 -1.92  (-78.31 %)2022 Q3
6/30/2022-1.68 -2.04  (-21.09 %)2022 Q2
3/31/2022-1.89 -2.19  (-15.85 %)2022 Q1
12/31/2021-1.38 -0.57  (58.61 %)2021 Q4
9/30/2021-0.39 -2.02  (-421.16 %)2021 Q3
6/30/2021-2.01 -1.9  (5.33 %)2021 Q2
3/31/2021-1.8 -2.29  (-27.11 %)2021 Q1
12/31/2020-1.98 -1.3  (34.35 %)2020 Q4
9/30/2020-1.54 -1.96  (-27.26 %)2020 Q3
6/30/2020-1.72 -1.38  (19.89 %)2020 Q2
1
2
3

Albireo Pharma list of shareholders

%
Name
Stocks
Change
Date
9.43 % Federated Hermes Global Investment Management Corp.1,956,488-301,63612/31/2022
8.47 % Perceptive Advisors LLC1,757,160-182,56312/31/2022
8.21 % Deep Track Capital LP1,704,000579,57912/31/2022
7.15 % Beryl Capital Management, LLC1,483,5991,483,5992/16/2023
6.57 % Chicago Capital, LLC1,362,484242,71012/31/2022
5.59 % BlackRock Institutional Trust Company, N.A.1,159,92491,38812/31/2022
5.18 % Carlson Capital, L.P.1,075,0001,075,0002/17/2023
4.82 % Millennium Management LLC999,363611,7962/21/2023
4.56 % The Vanguard Group, Inc.945,22731,05212/31/2022
4.46 % Franklin Advisers, Inc.924,773-48712/31/2022
1
2
3
4
5
...
10

Albireo Pharma Executives and Management Board

Mr. Ronald Cooper59
Albireo Pharma President, Chief Executive Officer, Director (since 2016)
Compensation 6.04 M
Ms. Pamela Stephenson54
Albireo Pharma Chief Commercial Officer
Compensation 1.96 M
Ms. Martha Carter69
Albireo Pharma Chief Regulatory Officer
Compensation 1.73 M
Mr. Simon Harford61
Albireo Pharma Chief Financial Officer, Treasurer
Compensation 1.71 M
Dr. Jan Mattsson57
Albireo Pharma Chief Scientific Officer
Compensation 1.4 M
1
2
3

Albireo Pharma Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
Gen Ilac Sag Ur Stock
Gen Ilac Sag Ur
SupplierCustomer0,760,31-0,200,21--
Eisai Stock
Eisai
SupplierCustomer0,060,540,55-0,600,260,17
Travere Therapeutics Stock
Travere Therapeutics
SupplierCustomer-0,530,120,63-0,02-0,400,01
Biocon Stock
Biocon
SupplierCustomer-0,630,640,280,070,310,52
1

Most common questions regarding Albireo Pharma

What values and corporate philosophy does Albireo Pharma represent?

Albireo Pharma Inc represents core values of integrity, innovation, and collaboration in the pharmaceutical industry. Committed to improving patient lives, Albireo Pharma focuses on developing and commercializing therapeutic products for rare pediatric liver diseases and gastrointestinal disorders. With a patient-centric approach, the company aims to provide effective treatment options and groundbreaking solutions. Albireo Pharma's corporate philosophy is driven by its dedication to scientific excellence, ethical conduct, and maintaining strong partnerships within the healthcare community.

In which countries and regions is Albireo Pharma primarily present?

Albireo Pharma Inc is primarily present in the United States, with its headquarters located in Boston, Massachusetts. As a biopharmaceutical company, Albireo focuses on developing and commercializing novel bile acid modulators to treat rare pediatric liver diseases and gastrointestinal disorders. With a strong presence in the US, Albireo Pharma Inc is dedicated to bringing innovative therapies to patients in need, and its expanding pipeline showcases its commitment to advancing medical treatment options in this region.

What significant milestones has the company Albireo Pharma achieved?

Albireo Pharma Inc has achieved significant milestones since its establishment. The company has successfully developed and gained regulatory approval for its lead product, Odevixibat, which is indicated for the treatment of progressive familial intrahepatic cholestasis. Albireo has also secured partnerships with key pharmaceutical companies, further enhancing its market presence and global reach. The company's commitment to innovation and clinical advancements has resulted in positive clinical trial results and numerous publications in reputed medical journals. Albireo Pharma Inc continues to demonstrate its dedication to improving patient outcomes through ongoing research and development efforts.

What is the history and background of the company Albireo Pharma?

Albireo Pharma Inc. is a pharmaceutical company known for its focus on developing and commercializing innovative therapies for liver diseases. Founded in 2008, Albireo Pharma is headquartered in Boston, Massachusetts. The company is committed to improving the lives of patients suffering from rare and orphan liver diseases through its research and development efforts. Albireo Pharma has a strong portfolio of experimental drugs, including A4250, aimed at addressing cholestatic liver diseases. With a team of experienced professionals, Albireo Pharma strives to advance its pipeline and bring novel treatments to the market to positively impact patients in need.

Who are the main competitors of Albireo Pharma in the market?

The main competitors of Albireo Pharma Inc in the market include companies like AstraZeneca, Gilead Sciences, Intercept Pharmaceuticals, and Novartis.

In which industries is Albireo Pharma primarily active?

Albireo Pharma Inc is primarily active in the pharmaceutical industry.

What is the business model of Albireo Pharma?

The business model of Albireo Pharma Inc. revolves around developing and commercializing novel therapeutics to treat rare pediatric liver diseases and gastrointestinal (GI) disorders. Albireo's innovative approach focuses on targeting bile acid biology, aiming to improve the quality of life for patients. By harnessing their deep understanding of bile acid physiology, the company develops new chemical entities that modulate bile acid homeostasis, providing potential treatments for conditions such as progressive familial intrahepatic cholestasis (PFIC) and Alagille syndrome. Albireo Pharma Inc. aims to address unmet medical needs in the field of rare pediatric liver and GI disorders through their research, development, and commercialization efforts.

What is the P/E ratio of Albireo Pharma 2024?

The Albireo Pharma P/E ratio is -10.87.

What is the P/S ratio of Albireo Pharma 2024?

The Albireo Pharma P/S ratio is 5.72.

What is the AlleAktien quality score of Albireo Pharma?

The AlleAktien quality score for Albireo Pharma is 5/10.

What is the revenue of Albireo Pharma 2024?

The expected Albireo Pharma revenue is 148.29 M USD.

How high is the profit of Albireo Pharma 2024?

The expected Albireo Pharma profit is -78.08 M USD.

What is the business model of Albireo Pharma

Albireo Pharma Inc is a biopharmaceutical company specializing in the development and commercialization of therapeutics for the treatment of liver diseases and pediatric metabolic disorders. The company operates in Europe and the US and aims to find innovative solutions to improve the quality of life for patients worldwide. The company has three main business areas: 1. Pediatric metabolic disorders: This area involves the development of therapeutics for rare genetic metabolic disorders, aiming to enable children to survive and have an improved quality of life. The company has already released an approved treatment called Bylvay, which is used for patients with bile acid synthesis defects type 1. Other developments are in the pipeline, including a drug for treating Progressive Familial Intrahepatic Cholestasis Long-term (PFIC L). 2. Liver diseases: Albireo Pharma Inc develops therapeutics to treat liver diseases that occur in both pediatrics and adults. It focuses particularly on conditions where improvement in bile flow is needed, such as pruritus hepatis or primary biliary cholangitis. The drug Odevixibat is being developed to promote bile flow. 3. Research and development: The company utilizes state-of-the-art research methods to develop innovative therapeutics for liver diseases and pediatric metabolic disorders. This includes the development of technologies for more effective drug administration and collaboration with other companies to make the development process more efficient. Albireo's business model is based on the research and development of therapeutics. The company invests a significant portion of its revenue in developing new drugs and building partnerships with other companies to bring them to market more effectively. At the same time, attracting investors and well-known venture capital firms is an important part of the business model. It aims to secure funding for research and development to bring the products to market. In terms of the products offered by Albireo Pharma Inc, there are a variety of drugs that can be utilized in different areas. Bylvay and Odevixibat are among the most significant drugs currently being developed and are already inevitable in the market. However, the research and development of new therapeutics remains an important aspect of the business model, as the company strives to establish a reputation as a frontrunner in the healthcare industry. In summary, Albireo Pharma Inc is an innovative company dedicated to the development of therapeutics to achieve a better quality of life for those with liver diseases and pediatric metabolic disorders. The company invests in research and development of new drugs and collaborates closely with other companies to bring them to market. Its goal is to make significant changes in the healthcare industry and become a reputable company in the field.

What is the Albireo Pharma dividend?

Albireo Pharma pays a dividend of 0 USD distributed over payouts per year.

How often does Albireo Pharma pay dividends?

The dividend cannot currently be calculated for Albireo Pharma or the company does not pay out a dividend.

What is the Albireo Pharma ISIN?

The ISIN of Albireo Pharma is US01345P1066.

What is the Albireo Pharma WKN?

The WKN of Albireo Pharma is A2DF99.

What is the Albireo Pharma ticker?

The ticker of Albireo Pharma is ALBO.

How much dividend does Albireo Pharma pay?

Over the past 12 months, Albireo Pharma paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Albireo Pharma is expected to pay a dividend of 0 USD.

What is the dividend yield of Albireo Pharma?

The current dividend yield of Albireo Pharma is .

When does Albireo Pharma pay dividends?

Albireo Pharma pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Albireo Pharma?

Albireo Pharma paid dividends every year for the past 0 years.

What is the dividend of Albireo Pharma?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Albireo Pharma located?

Albireo Pharma is assigned to the 'Health' sector.

Wann musste ich die Aktien von Albireo Pharma kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Albireo Pharma from 8/26/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 8/26/2024.

When did Albireo Pharma pay the last dividend?

The last dividend was paid out on 8/26/2024.

What was the dividend of Albireo Pharma in the year 2023?

In the year 2023, Albireo Pharma distributed 0 USD as dividends.

In which currency does Albireo Pharma pay out the dividend?

The dividends of Albireo Pharma are distributed in USD.

All fundamentals about Albireo Pharma

Our stock analysis for Albireo Pharma Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Albireo Pharma Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.